PHARMACEUTICAL 2025

Abbott Laboratories
Rank 11 of 225

Abbott



TOP RATED 2025

RealRate

PHARMACEUTICAL 2025

Abbott Laboratories
Rank 11 of 225

Abbott

The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abbott Laboratories compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 110% points.The greatest weakness of Abbott Laboratories is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 392%, being 178% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	23,656,000
Cost of Goods Sold	18,706,000
Intangible Assets	29,755,000
Liabilities, Current	14,157,000
Liabilities, Non-Current	0
Other Assets	17,345,000
Other Compr. Net Income	-67,000
Other Expenses	-3,952,000
Other Liabilities	0
Other Net Income	747,000
Other Revenues	41,950,000
Property and Equipment	10,658,000
Research and Development	2,844,000
Selling, General and Administrative Expense	11,697,000

Output Variable	Value in 1000 USD
Assets	81,414,000
Liabilities	14,157,000
Expenses	29,295,000
Revenues	41,950,000
Stockholders Equity	67,257,000
Net Income	13,402,000
Comprehensive Net Income	13,368,500
BaseVar	83,815,000
ECR before LimitedLiability	335%
Economic Capital Ratio	392%